Baudax Bio Inc.

1.03-0.0408-3.81%Vol 788.39K1Y Perf -56.14%
Apr 19th, 2021 14:43 DELAYED
BID1.02 ASK1.03
Open1.04 Previous Close1.07
Pre-Market- After-Market-
 - -%  - -
Target Price
7.33 
Analyst Rating
Strong Buy 1.00
Potential %
615.12 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap72.19M 
Earnings Rating
Price Range Ratio 52W %
1.49 
Earnings Date
14th May 2021

Today's Price Range

1.011.07

52W Range

0.97004.95

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-8.55%
1 Month
-29.14%
3 Months
-17.69%
6 Months
-60.22%
1 Year
-56.14%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BXRX1.03-0.0408-3.81
AAPL134.420.26000.19
GOOG2 299.942.18000.09
MSFT258.74-2.0000-0.77
XOM56.21-0.4500-0.79
WFC44.270.43000.98
JNJ162.670.43000.27
FB301.75-4.4300-1.45
GE13.390.00000.00
JPM153.08-0.2200-0.14
Earnings HistoryEstimateReportedSurprise %
Q03 2020-0.84-0.7214.29
Q02 2020-0.74-0.740.00
Q01 2020-0.91-0.838.79
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date14th May 2021
Estimated EPS Next Report-0.19
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume788.39K
Shares Outstanding70.14M
Trades Count1.56K
Dollar Volume6.62M
Avg. Volume5.32M
Avg. Weekly Volume1.35M
Avg. Monthly Volume1.62M
Avg. Quarterly Volume4.97M

Baudax Bio Inc. (NASDAQ: BXRX) stock closed at 1.07 per share at the end of the most recent trading day (a 0.94% change compared to the prior day closing price) with a volume of 1.69M shares and market capitalization of 72.19M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 57 people. Baudax Bio Inc. CEO is Gerri A. Henwood.

The one-year performance of Baudax Bio Inc. stock is -56.14%, while year-to-date (YTD) performance is 5.94%. BXRX stock has a five-year performance of %. Its 52-week range is between 0.97 and 4.95, which gives BXRX stock a 52-week price range ratio of 1.49%

Baudax Bio Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 153.66, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -123.79%, a ROC of -% and a ROE of 482.87%. The company’s profit margin is -%, its EBITDA margin is -11 018.70%, and its revenue ttm is $493.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Baudax Bio Inc., there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.19 for the next earnings report. Baudax Bio Inc.’s next earnings report date is 14th May 2021.

The consensus rating of Wall Street analysts for Baudax Bio Inc. is Strong Buy (1), with a target price of $7.33, which is +615.12% compared to the current price. The earnings rating for Baudax Bio Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Baudax Bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Baudax Bio Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 25.62, ATR14 : 0.14, CCI20 : -137.71, Chaikin Money Flow : 0.06, MACD : -0.11, Money Flow Index : 24.30, ROC : -16.41, RSI : 39.35, STOCH (14,3) : 17.38, STOCH RSI : 0.32, UO : 42.24, Williams %R : -82.62), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Baudax Bio Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Baudax Bio Inc.

Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings.

CEO: Gerri A. Henwood

Telephone: +1 484 395-2470

Address: 490 Lapp Road, Malvern 19355, PA, US

Number of employees: 57

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

54%46%

Bearish Bullish

55%45%

News

Stocktwits